Global gene expression and functional network analysis of gastric cancer identify extended pathway maps and GPRC5A as a potential biomarker

Cancer Letters

Volumn 326, Issue 1, 2012, Pages 105-113

  Cheng, Lei ^a,b   Yang, Sheng ^a,c   Yang, Yanqing ^a   Zhang, Wen ^b   Xiao, Huasheng ^b   Gao, Hengjun ^b,d   Deng, Xiaxing ^a   Zhang, Qinghua ^a,e  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b NATIONAL ENGINEERING CENTER FOR BIOCHIP AT SHANGHAI   (China)

^c Laboratory of Shanghai Skin Diseases Hospital   (China)

^d TONGJI HOSPITAL OF TONGJI UNIVERSITY   (China)

^e Wayen Biotechnologies Inc   (China)

Author keywords

Biomarker; Expression microarray; Gastric cancer; Network analysis; Pathway

Indexed keywords

G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 5A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; JANUS KINASE; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; PROTEIN TYROSINE KINASE; RAS PROTEIN; STAT PROTEIN; TUMOR MARKER; UNCLASSIFIED DRUG; WNT PROTEIN;

APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER TISSUE; CLINICAL ARTICLE; CONTROLLED STUDY; COPY NUMBER VARIATION; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE MAPPING; GENETIC REGULATION; GPRC5A GENE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SERPINH1 GENE; SIGNAL TRANSDUCTION; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR VASCULARIZATION; UNQ473 GENE;

ADULT; AGED; APOPTOSIS; CELL PROLIFERATION; DNA COPY NUMBER VARIATIONS; FEMALE; GENE EXPRESSION PROFILING; HUMANS; MALE; MIDDLE AGED; NEOVASCULARIZATION, PHYSIOLOGIC; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECEPTORS, G-PROTEIN-COUPLED; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 84866171256     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2012.07.031     Document Type: Article

References (54)

1. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
2. Myllykangas S., Junnila S., Kokkola A., Autio R., Scheinin I., Kiviluoto T., Karjalainen-Lindsberg M.L., Hollmen J., Knuutila S., Puolakkainen P., Monni O. Integrated gene copy number and expression microarray analysis of gastric cancer highlights potential target genes. Int. J. Cancer 2008, 123:817-825.
3. Brenner H., Rothenbacher D., Arndt V. Epidemiology of stomach cancer. Methods Mol. Biol. 2009, 472:467-477.
4. Leung W.K., Wu M.S., Kakugawa Y., Kim J.J., Yeoh K.G., Goh K.L., Wu K.C., Wu D.C., Sollano J., Kachintorn U., Gotoda T., Lin J.T., You W.C., Ng E.K., Sung J.J. Screening for gastric cancer in Asia: current evidence and practice. Lancet Oncol. 2008, 9:279-287.
5. Chen C.N., Lin J.J., Chen J.J., Lee P.H., Yang C.Y., Kuo M.L., Chang K.J., Hsieh F.J. Gene expression profile predicts patient survival of gastric cancer after surgical resection. J. Clin. Oncol. 2005, 23:7286-7295.
6. Marchet A., Mocellin S., Belluco C., Ambrosi A., DeMarchi F., Mammano E., Digito M., Leon A., D'Arrigo A., Lise M., Nitti D. Gene expression profile of primary gastric cancer: towards the prediction of lymph node status. Ann. Surg. Oncol. 2007, 14:1058-1064.
7. Vecchi M., Nuciforo P., Romagnoli S., Confalonieri S., Pellegrini C., Serio G., Quarto M., Capra M., Roviaro G.C., Contessini Avesani E., Corsi C., Coggi G., Di Fiore P.P., Bosari S. Gene expression analysis of early and advanced gastric cancers. Oncogene 2007, 26:4284-4294.
8. Junnila S., Kokkola A., Mizuguchi T., Hirata K., Karjalainen-Lindsberg M.L., Puolakkainen P., Monni O. Gene expression analysis identifies over-expression of CXCL1, SPARC, SPP1, and SULF1 in gastric cancer. Genes Chromosom. Cancer 2010, 49:28-39.
9. Cheng L., Wang P., Yang S., Yang Y., Zhang Q., Zhang W., Xiao H., Gao H. Identification of genes with a correlation between copy number and expression in gastric cancer. BMC Med. Genomics 2012, 5:14.
10. Edgar R., Domrachev M., Lash A.E. Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucl. Acids Res. 2002, 30:207-210.
11. Saeed A.I., Bhagabati N.K., Braisted J.C., Liang W., Sharov V., Howe E.A., Li J., Thiagarajan M., White J.A., Quackenbush J. TM4 microarray software suite. Methods Enzymol. 2006, 411:134-193.
12. Huang da W., Sherman B.T., Lempicki R.A. Systematic and integrative analysis of large gene lists using DAVID bioinformatics resources. Nat. Protoc. 2009, 4:44-57.
13. Huang da W., Sherman B.T., Lempicki R.A. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists. Nucl. Acids Res. 2009, 37:1-13.
14. Kanehisa M., Goto S., Furumichi M., Tanabe M., Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucl. Acids Res. 2010, 38:D355-360.
15. Ooi C.H., Ivanova T., Wu J., Lee M., Tan I.B., Tao J., Ward L., Koo J.H., Gopalakrishnan V., Zhu Y., Cheng L.L., Lee J., Rha S.Y., Chung H.C., Ganesan K., So J., Soo K.C., Lim D., Chan W.H., Wong W.K., Bowtell D., Yeoh K.G., Grabsch H., Boussioutas A., Tan P. Oncogenic pathway combinations predict clinical prognosis in gastric cancer. PLoS Genet. 2009, 5:e1000676.
16. Cerami E.G., Gross B.E., Demir E., Rodchenkov I., Babur O., Anwar N., Schultz N., Bader G.D., Sander C. Pathway commons, a web resource for biological pathway data. Nucl. Acids Res. 2011, 39:D685-690.
17. M. Safran, I. Dalah, J. Alexander, N. Rosen, T. Iny Stein, M. Shmoish, N. Nativ, I. Bahir, T. Doniger, H. Krug, A. Sirota-Madi, T. Olender, Y. Golan, G. Stelzer, A. Harel, D. Lancet, GeneCards Version 3: the human gene integrator. Database (Oxford) 2010 (2010) baq020.
18. Yang Y.Q., Zhang L.J., Dong H., Jiang C.L., Zhu Z.G., Wu J.X., Wu Y.L., Han J.S., Xiao H.S., Gao H.J., Zhang Q.H. Upregulated expression of S100A6 in human gastric cancer. J. Dig. Dis. 2007, 8:186-193.
19. Zhao Z.S., Wang Y.Y., Chu Y.Q., Ye Z.Y., Tao H.Q. SPARC is associated with gastric cancer progression and poor survival of patients. Clin. Cancer Res. 2010, 16:260-268.
20. Kwon M.J., Kim S.H., Jeong H.M., Jung H.S., Kim S.S., Lee J.E., Gye M.C., Erkin O.C., Koh S.S., Choi Y.L., Park C.K., Shin Y.K. Claudin-4 overexpression is associated with epigenetic derepression in gastric carcinoma. Lab. Invest. 2011, 91:1652-1667.
21. Kaneda A., Kaminishi M., Sugimura T., Ushijima T. Decreased expression of the seven ARP2/3 complex genes in human gastric cancers. Cancer Lett. 2004, 212:203-210.
22. Chen Q., Chen X., Zhang M., Fan Q., Luo S., Cao X. MiR-137 is frequently down-regulated in gastric cancer and is a negative regulator of Cdc42. Dig. Dis. Sci. 2011, 56:2009-2016.
23. Takeno A., Takemasa I., Doki Y., Yamasaki M., Miyata H., Takiguchi S., Fujiwara Y., Matsubara K., Monden M. Integrative approach for differentially overexpressed genes in gastric cancer by combining large-scale gene expression profiling and network analysis. Br. J. Cancer 2008, 99:1307-1315.
24. Johnson A.H., Frierson H.F., Zaika A., Powell S.M., Roche J., Crowe S., Moskaluk C.A., El-Rifai W. Expression of tight-junction protein claudin-7 is an early event in gastric tumorigenesis. Am. J. Pathol. 2005, 167:577-584.
25. Rendon-Huerta E., Teresa F., Teresa G.M., Xochitl G.S., Georgina A.F., Veronica Z.Z., Montano L.F. Distribution and expression pattern of claudins 6, 7, and 9 in diffuse- and intestinal-type gastric adenocarcinomas. J. Gastrointest. Cancer 2010, 41:52-59.
26. Park J.Y., Park K.H., Oh T.Y., Hong S.P., Jeon T.J., Kim C.H., Park S.W., Chung J.B., Song S.Y., Bang S. Up-regulated claudin 7 expression in intestinal-type gastric carcinoma. Oncol. Rep. 2007, 18:377-382.
27. Hewitt K.J., Agarwal R., Morin P.J. The claudin gene family: expression in normal and neoplastic tissues. BMC Cancer 2006, 6:186.
28. Saeki N., Gu J., Yoshida T., Wu X. Prostate stem cell antigen: a Jekyll and Hyde molecule?. Clin. Cancer Res. 2010, 16:3533-3538.
29. Qiao L., Feng Y. Genetic variations of prostate stem cell antigen (PSCA) contribute to the risk of gastric cancer for Eastern Asians: a meta-analysis based on 16792 individuals. Gene 2012, 493:83-91.
30. Wang M., Bai J., Tan Y., Wang S., Tian Y., Gong W., Zhou Y., Gao Y., Zhou J., Zhang Z. Genetic variant in PSCA predicts survival of diffuse-type gastric cancer in a Chinese population. Int. J. Cancer 2011, 129:1207-1213.
31. Lu Y., Chen J., Ding Y., Jin G., Wu J., Huang H., Deng B., Hua Z., Zhou Y., Shu Y., Liu P., Hu Z., Shen J., Xu Y., Shen H. Genetic variation of PSCA gene is associated with the risk of both diffuse- and intestinal-type gastric cancer in a Chinese population. Int. J. Cancer 2010, 127:2183-2189.
32. Sakamoto H., Yoshimura K., Saeki N., Katai H., Shimoda T., Matsuno Y., Saito D., Sugimura H., Tanioka F., Kato S., Matsukura N., Matsuda N., Nakamura T., Hyodo I., Nishina T., Yasui W., Hirose H., Hayashi M., Toshiro E., Ohnami S., Sekine A., Sato Y., Totsuka H., Ando M., Takemura R., Takahashi Y., Ohdaira M., Aoki K., Honmyo I., Chiku S., Aoyagi K., Sasaki H., Yanagihara K., Yoon K.A., Kook M.C., Lee Y.S., Park S.R., Kim C.G., Choi I.J., Yoshida T., Nakamura Y., Hirohashi S. Genetic variation in PSCA is associated with susceptibility to diffuse-type gastric cancer. Nat. Genet. 2008, 40:730-740.
33. Hiraoka N., Yamazaki-Itoh R., Ino Y., Mizuguchi Y., Yamada T., Hirohashi S., Kanai Y. CXCL17 and ICAM2 are associated with a potential anti-tumor immune response in early intraepithelial stages of human pancreatic carcinogenesis. Gastroenterology 2011, 140:310-321.
34. Mu X., Chen Y., Wang S., Huang X., Pan H., Li M. Overexpression of VCC-1 gene in human hepatocellular carcinoma cells promotes cell proliferation and invasion. Acta Biochim. Biophys. Sin. (Shanghai) 2009, 41:631-637.
35. Weinstein E.J., Head R., Griggs D.W., Sun D., Evans R.J., Swearingen M.L., Westlin M.M., Mazzarella R. VCC-1, a novel chemokine, promotes tumor growth. Biochem. Biophys. Res. Commun. 2006, 350:74-81.
36. Cui J., Chen Y., Chou W.C., Sun L., Chen L., Suo J., Ni Z., Zhang M., Kong X., Hoffman L.L., Kang J., Su Y., Olman V., Johnson D., Tench D.W., Amster I.J., Orlando R., Puett D., Li F., Xu Y. An integrated transcriptomic and computational analysis for biomarker identification in gastric cancer. Nucl. Acids Res. 2011, 39:1197-1207.
37. Wang Q., Wen Y.G., Li D.P., Xia J., Zhou C.Z., Yan D.W., Tang H.M., Peng Z.H. Upregulated INHBA expression is associated with poor survival in gastric cancer. Med. Oncol. 2012, 29:77-83.
38. Hirai K., Kikuchi S., Kurita A., Ohashi S., Adachi E., Matsuoka Y., Nagata K., Watanabe M. Immunohistochemical distribution of heat shock protein 47 (HSP47) in scirrhous carcinoma of the stomach. Anticancer Res. 2006, 26:71-78.
39. Zhang X., Yang J.J., Kim Y.S., Kim K.Y., Ahn W.S., Yang S. An 8-gene signature, including methylated and down-regulated glutathione peroxidase 3, of gastric cancer. Int. J. Oncol. 2010, 36:405-414.
40. Araki K., Mikami T., Yoshida T., Kikuchi M., Sato Y., Oh-ishi M., Kodera Y., Maeda T., Okayasu I. High expression of HSP47 in ulcerative colitis-associated carcinomas: proteomic approach. Br. J. Cancer 2009, 101:492-497.
41. Kwon Y.J., Lee S.J., Koh J.S., Kim S.H., Kim Y.J., Park J.H. Expression patterns of aurora kinase B, heat shock protein 47, and periostin in esophageal squamous cell carcinoma. Oncol. Res. 2009, 18:141-151.
42. Nese N., Kandiloglu A.R., Simsek G., Lekili M., Ozdamar A., Catalkaya A., Coskun T. Comparison of the desmoplastic reaction and invading ability in invasive ductal carcinoma of the breast and prostatic adenocarcinoma based on the expression of heat shock protein 47 and fascin. Anal. Quant. Cytol. Histol. 2010, 32:90-101.
43. Maitra A., Iacobuzio-Donahue C., Rahman A., Sohn T.A., Argani P., Meyer R., Yeo C.J., Cameron J.L., Goggins M., Kern S.E., Ashfaq R., Hruban R.H., Wilentz R.E. Immunohistochemical validation of a novel epithelial and a novel stromal marker of pancreatic ductal adenocarcinoma identified by global expression microarrays: sea urchin fascin homolog and heat shock protein 47. Am. J. Clin. Pathol. 2002, 118:52-59.
44. Yang Q., Liu S., Tian Y., Hasan C., Kersey D., Salwen H.R., Chlenski A., Perlman E.J., Cohn S.L. Methylation-associated silencing of the heat shock protein 47 gene in human neuroblastoma. Cancer Res. 2004, 64:4531-4538.
45. Nagahata T., Sato T., Tomura A., Onda M., Nishikawa K., Emi M. Identification of RAI3 as a therapeutic target for breast cancer. Endocr. Relat. Cancer 2005, 12:65-73.
46. Jorissen H., Bektas N., Dahl E., Hartmann A., ten Haaf A., Di Fiore S., Kiefer H., Thess A., Barth S., Klockenbring T. Production and characterisation of monoclonal antibodies against RAI3 and its expression in human breast cancer. BMC Cancer 2009, 9:200.
47. Tao Q., Fujimoto J., Men T., Ye X., Deng J., Lacroix L., Clifford J.L., Mao L., Van Pelt C.S., Lee J.J., Lotan D., Lotan R. Identification of the retinoic acid-inducible Gprc5a as a new lung tumor suppressor gene. J. Natl. Cancer Inst. 2007, 99:1668-1682.
48. Kadara H., Fujimoto J., Men T., Ye X., Lotan D., Lee J.S., Lotan R. A Gprc5a tumor suppressor loss of expression signature is conserved, prevalent, and associated with survival in human lung adenocarcinomas. Neoplasia 2010, 12:499-505.
49. Dang C.V., O'Donnell K.A., Zeller K.I., Nguyen T., Osthus R.C., Li F. The c-Myc target gene network. Semin. Cancer Biol. 2006, 16:253-264.
50. Fuhrmann G., Rosenberger G., Grusch M., Klein N., Hofmann J., Krupitza G. The MYC dualism in growth and death. Mutat. Res. 1999, 437:205-217.
51. Nesbit C.E., Tersak J.M., Prochownik E.V. MYC oncogenes and human neoplastic disease. Oncogene 1999, 18:3004-3016.
52. Dang C.V. C-Myc target genes involved in cell growth, apoptosis, and metabolism. Mol. Cell. Biol. 1999, 19:1-11.
53. Zeller K.I., Jegga A.G., Aronow B.J., O'Donnell K.A., Dang C.V. An integrated database of genes responsive to the Myc oncogenic transcription factor: identification of direct genomic targets. Genome Biol. 2003, 4:R69.
54. Bajou K., Masson V., Gerard R.D., Schmitt P.M., Albert V., Praus M., Lund L.R., Frandsen T.L., Brunner N., Dano K., Fusenig N.E., Weidle U., Carmeliet G., Loskutoff D., Collen D., Carmeliet P., Foidart J.M., Noel A. The plasminogen activator inhibitor PAI-1 controls in vivo tumor vascularization by interaction with proteases, not vitronectin. Implications for antiangiogenic strategies. J. Cell Biol. 2001, 152:777-784.